The SUPPORT Act and Healthcare Providers—A First Look

by Morgan Lewis
Contact

Morgan Lewis

The newly enacted SUPPORT Act’s wide-ranging provisions take aim at the entire healthcare continuum, including providers, who will be on the front lines of change as the new law takes effect. The law includes amendments to Medicare and Medicaid, and changes affecting program integrity and transparency reporting of provider payments by drug and device manufacturers and the disposal of unused medication.

Earlier today, October 24, US President Donald Trump signed Congress’s long-anticipated response to the national opioid crisis into law. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (HR 6)—a product of rare broad bipartisan support in both the House of Representatives (393-8) and the Senate (98-1)—is perhaps the most significant piece of public health legislation to pass during the 115th Congress (2017–2018).

The SUPPORT Act is the product of more than 120 separate bills and the culmination of nearly two years of work across multiple committees by a number of lawmakers in the House and Senate. This achievement reflects the breadth of the opioid crisis, which claimed 72,000 lives across the country last year alone, as well as the collective resolve of Congress to address those challenges.

Broad in scope, the legislation’s wide-ranging provisions take aim at the entire healthcare continuum, including providers, who will be on the front lines as the law reshapes the treatment and prevention of prescription drug abuse disorders. Providers should be aware of changes in the law that affect program integrity, Medicare, Medicaid, transparency reporting of provider payments by drug and device manufacturers, and the disposal of unused medication. The legislation also calls for numerous grants and countless reviews, reports, and studies that are certain to result in additional health system changes.

Implementation will occur over the course of a few years and many of the new law’s provisions have their own effective dates. Unless otherwise stated, the new law is effective upon enactment.

Program Integrity

New Criminal Anti-Kickback Provisions for Private Health Benefit Programs Serving Recovery Homes, Clinical Treatment Facilities, and Labs

In addition to other fraud and deceptive practice prohibitions, Section 8121 of the SUPPORT Act introduces a new criminal felony referral prohibition to combat patient brokering activities and abusive payment arrangements for opioid treatment services involving laboratories, recovery homes, and clinical treatment facilities. This provision, known as the Eliminating Kickbacks in Recovery Act of 2018, effectively extends federal anti-kickback–style prohibitions to the private market for these areas. Title 18 of the United States Code is amended to add Section 220, “Illegal remunerations for referrals to recovery homes, clinical treatment facilities and laboratories.”

While it does not overlap with the federal anti-kickback statute that applies to federal healthcare programs such as Medicare and Medicaid, the SUPPORT Act anti-referral prohibition accomplishes a broad entry into regulating arrangements and relationships in the private market for conflicts of interest in referrals involving health benefit programs, defined as “any public or private plan or contract, affecting commerce, under which any medical benefit, item, or service is provided to any individual, and includes any individual or entity who is providing a medical benefit, item, or service for which payment may be made under the plan or contract.”

The private referral prohibition extends to any individual or entity that

  • solicits or receives any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory; or
  • pays or offers any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind,
    • to induce a referral of an individual to a recovery home, clinical treatment facility, or laboratory or
    • in exchange for an individual using the services of that recovery home, clinical treatment facility, or laboratory.

Violation of the referral prohibition is punishable by a fine of not more than $200,000 and imprisonment of not more than 10 years for each occurrence. Notably, this provision does not apply in instances where the federal anti-kickback statute may apply, nor does it preempt state anti-kickback regulations. It is also clear that for now the referral prohibition only applies to recovery homes, clinical treatment facilities, and laboratories, but could be amended to apply to other health industry private sector arrangements in the future.

Like the anti-kickback statute, Congress has recognized certain statutory exceptions that exempt remuneration or arrangements from the referral prohibition ambit, but notably authorizes the US attorney general to create exceptions, or clarify any exceptions by regulation, in consultation with the secretary of the US Department of Health and Human Services (HHS), rather than authorizing HHS, which is the agency responsible for safe harbor guidance for the federal anti-kickback statute, to do this alone. The SUPPORT Act currently includes the following exceptions to the referral prohibition:

  • Properly disclosed discounts under healthcare benefit programs that reflect a reduction in price of the costs claimed or charges made by the provider or entity
  • Payments by employers to bona fide employees or independent contractors if the payment is not determined by or does not vary by the number of individuals referred to the provider, the number of tests or procedures performed, or the amount billed to or received from individuals referred to the provider
  • Drug discounts under the Medicare coverage gap discount program
  • Payments for services under personal services and management contracts meeting the requirements of the federal anti-kickback statute’s regulatory safe harbor for personal services and management contracts, 42 CFR 1001.952(d) (i.e., payment is in writing for at least one year for compensation at fair market value in a commercially reasonable transaction that does not take into account the volume or value of referrals)
  • Specific coinsurance or copayment waivers and discounts
  • Federally qualified health center arrangements meeting the anti-kickback statute exceptions
  • Any payment made pursuant to an alternative payment model or payment arrangement that the secretary of HHS determines is necessary for care coordination or value-based care

Though there are some structural similarities to the anti-kickback statute, the statutes are distinct on key issues affecting providers in this area largely aimed at prohibiting or restricting productivity compensation or any compensation related to referrals. For example, the new law provides an exception for payments by employers to bona fide employees or independent contractors, which is a narrower exception than for compensation regulated by the federal anti-kickback statute exception. The federal anti-kickback statute exception for bona fide employees protects any payments related to the furnishing of covered items or services that are reimbursed in whole or part by federal healthcare programs—a scope that corresponds with the anti-kickback statute. In contrast, the prohibitions in the Eliminating Kickbacks in Recovery Act of 2018 will not exempt compensation to employees or independent contractors that varies by the number of patients referred or tests performed or any benchmark to referrals. This provision would appear to prohibit productivity compensation models.

In further regulating compensation arrangements, personal services and management contracts are required to meet the requirements of the federal anti-kickback statute safe harbor for personal services and management contracts, 42 CFR 1001.952(d), with no provision suggesting that compliance with these requirements is voluntary or may be substantially accomplished and still be legal. Under the federal anti-kickback statute, the safe harbor provisions are not mandatory nor is any noncompliance alone sufficient to render an arrangement per se illegal. In the event an arrangement does not comply with the federal anti-kickback statute safe harbor requirements, the contracting parties may not claim immunity from criminal prosecution, but they may defend the arrangement on the basis of a “facts and circumstances” test that takes into account important factors such as whether the arrangement encourages overutilization or unfair competition or distorts patient choice.

Compliance with anti-kickback statute safe harbors is generally viewed as difficult for part-time, per diem, or other nontraditional arrangements. The statutory language requiring that any personal services arrangement meet the federal anti-kickback statute safe harbor goes much further than the statute itself by appearing to mandate full compliance with all of the anti-kickback statute safe harbor requirements under penalty of a criminal felony offense for any degree of noncompliance. The US Department of Justice, the agency given interpretative authority for the Eliminating Kickbacks in Recovery Act of 2018, should issue guidance to clarify the enforcement policy approach to the imported safe harbor requirements. Adopting the HHS Office of Inspector General legal approach to safe harbor compliance would be consistent with federal anti-kickback statute enforcement.

The Eliminating Kickbacks in Recovery Act of 2018 reflects long-held public health policy concerns on how financial considerations or conflicts of interest influence medical decisionmaking. In combating abusive patient brokering activities and payment arrangements, Congress has attempted to address the difficult area of productivity compensation and has reaffirmed that providers and entities should not make more money based on the number of patients referred or procedures or tests performed. These reform provisions will challenge many existing arrangements and require a new paradigm for compensated activities in the industry sector involving recovery homes, clinical treatment facilities, and laboratories.

“Fighting the Opioid Epidemic with Sunshine” Program

The Physician Payments Sunshine Act (Sunshine Act) requires certain drug and medical device manufacturers to annually report to the Centers for Medicare and Medicaid Services (CMS) payments and transfers of value made to physicians and teaching hospitals. This information is posted to and refreshed annually by CMS on the agency’s open payments webpage. The SUPPORT Act expands this reporting obligation to include payments and other transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives effective for payments reported in 2022, with payment tracking beginning in 2021.

This additional requirement is intended to enhance transparency with respect to industry relationships with advanced care practitioners who are increasingly involved in furnishing primary care, including prescribing opioids and other prescription drugs. The new law may also heighten law enforcement and regulatory scrutiny of such practitioners and their affiliated institutions as a safeguard against fraud and abuse and industry conflicts of interest. Like US-licensed physicians under the Sunshine Act, advanced care practitioners now will have to monitor the accuracy of their data reported to CMS by drug and device manufacturers and engage in the dispute resolution process if they believe there is an error.

Transparency Measures Under Medicare Parts C and D

The SUPPORT Act directs the secretary of HHS, not later than January 1, 2021, to annually notify “outlier prescribers” of opioids reflected on Part D claims, based on criteria established by the secretary, and subject to various exceptions including claims for individuals receiving hospice care and those undergoing cancer treatment. The new law authorizes funding for educating outlier prescribers on best practices for prescribing opioids including nonopioid pain management therapies. “Persistent” outlier prescribers may be subject to additional education and training requirements as determined by the secretary of HHS. Aggregate information on outlier prescribers (e.g., without prescriber names) will be posted to the CMS website.

The legislation requires the secretary of HHS to set up a secure portal to facilitate communications between the secretary, Part D and Medicare Advantage plans, and the Medicare drug integrity contractor (MEDIC) regarding program integrity. It also provides that plans must submit information on actions taken with respect to overprescribers of opioids and such other data as determined by the secretary of HHS. These provisions are effective no later than two years after enactment.

Medicare prescription drug plan sponsors may suspend payments to pharmacies pending the investigation of a credible allegation of fraud, effective January 1, 2020.

Medicare

Expanded Access to Screening, Prevention, and Treatment Services

The SUPPORT Act provides for a number of changes aimed at enhancing access to prescription drug abuse prevention and treatment services for Medicare beneficiaries. Starting January 1, 2020, newly eligible beneficiaries will be screened for risk factors related to opioid addiction as part of the initial “Welcome to Medicare” exam. Medicare Advantage and Part D prescription drug plans will include information on the risks associated with prolonged opioid use and coverage of non-pharmacological therapies, devices, and non-opioid medications to Medicare beneficiaries, either electronically or by mail, beginning for plan year 2021.

Effective January 1, 2020, Medicare coverage will be expanded to include medication assisted treatment (MAT) options furnished by opioid treatment programs (OPTs) certified and accredited by HHS. Currently, OPTs are not recognized as Medicare providers. Medicare will pay OPTs on a bundled basis for opioid use disorder treatments including dispensing and administering medications, toxicology testing, substance use counseling, and individual and group therapy.

Beneficiaries at risk for prescription drug abuse will be eligible for Medication Therapy Management (MTM), effective January 1, 2021. Part D plan sponsors will be required to adopt (as opposed to “voluntarily adopt” under current law) drug management programs for at-risk beneficiaries for plan years beginning in 2022. The SUPPORT Act requires CMS to identify Part D beneficiaries with a history of opioid-related overdose as potentially “at risk” for prescription drug abuse under the drug management program. At-risk beneficiaries may automatically escalate an appeal of this designation to an entity external to the plan.

A four-year demonstration project will be established by January 1, 2021 to test the effectiveness of “opioid use disorder care teams” in improving the physical and mental health outcomes for drug-addicted beneficiaries and, to the extent possible, reducing program expenditures. Individuals and entities eligible to participate in the care teams include physicians, group practices, and hospital outpatient departments. In implementing the demonstration project, preference will be given to entities and practitioners located in areas with higher levels of opioid use disorders than the national average.

Hospitals: New Guidance and an Action Plan

The SUPPORT Act directs the secretary of HHS to

  • post all guidance on prescribing opioids published by HHS on or after January 1, 2016, to the CMS website within 180 days of enactment;
  • publish a toolkit with guidance on pain management strategies and opioid use disorder prevention strategies for Part A hospitals by July 1, 2019; and
  • develop an “action plan” for addressing the opioid crisis that includes recommendations for payment and service delivery models to be tested by the Center for Medicare and Medicaid Innovation, and to report to Congress no later than January 1, 2020.

The new law requires the Medicare Payment Advisory Commission (MedPAC) to report to Congress by March 15, 2019, on how Medicare pays for opioid and non-opioid pain management treatments in inpatient and outpatient settings, including whether Medicare reimbursement provides financial incentives to prescribe opioids in place of a non-opioid alternative. To that end, the secretary of HHS is directed to review payment for outpatient surgical and pain management services and to begin making adjustments to avoid financial incentives to prescribe opioids in place of a non-opioid alternative for services furnished on or after January 1, 2020.

The secretary of HHS will also convene two panels of technical experts—one to review and provide recommendations on reducing surgical-setting opioid use, and the other to review and identify quality measurement gaps relating to opioids and opioid disorder treatments and to make recommendations regarding new measures, revisions to existing measures, and inclusion of such measures in value-based programs—within six months of enactment.

E-Prescribing and Prior Authorization Requirements

The SUPPORT Act requires e-prescribing for Schedule II, III, IV, or V controlled substances covered under a Part D or Medicare Advantage drug plan as well as secure electronic prior authorization for Part D covered drugs. Faxes or proprietary payer portals that do not meet standards defined by the secretary of HHS and electronic forms are not considered “electronic transmissions” for purposes of the prior authorization requirement. Both provisions are effective January 1, 2021.

Expanded Access to Telehealth

Beginning July 1, 2019, the geographic requirement that restricts telehealth services to Medicare beneficiaries located in rural or shortage areas will be eliminated.

Medicaid

Pregnant Women and Children

Since so many children are covered under state Medicaid programs, it is no surprise that the SUPPORT Act focuses on pregnant women and children in the numerous amendments to Medicaid. The titles of the various provisions in the table of contents tell the story alone, from setting up “Demonstration projects to increase substance use provider capacity under the Medicaid program” to enacting “Help for moms and babies.”

The law addresses infants with neonatal abstinence syndrome (NAS), introducing provisions that focus on incentivizing ways to decrease the incidence of NAS, and clarifying that state Medicaid programs can provide care for infants with NAS in pediatric recovery centers.

The legislation requests a Government Accountability Office (GAO) report that seeks best practices from the states with innovative, evidence-based payment models that focus on the prevention, screening, treatment, and self-care and post-discharge plans for mothers and fathers with substance use disorders and babies with NAS. To this end, the new law seeks guidance on suggested terminology and ICD codes to identify infants with NAS and neonatal withdrawal syndrome, which could include opioid withdrawal not requiring pharmacotherapy and withdrawal requiring pharmacotherapy.

The SUPPORT Act modifies Medicaid coverage for eligible pregnant and postpartum women receiving active treatment for substance use disorders at Medicaid Institutions for Mental Disease (IMDs) to provide that pregnant and postpartum women can continue to receive other Medicaid-covered care outside of the IMD, such as prenatal services.

The law requires amendments to Medicaid state plans to ensure states have programs in place that would monitor and manage the appropriate use of antipsychotic medications by children enrolled in the Medicaid program. It also aims to break down barriers that may limit access to care while being treated for substance use disorders at impatient mental health treatment facilitates with more than 16 beds, and expands eligibility under the Children’s Health Insurance Program (CHIP) for incarcerated youth.

Telehealth

Telehealth is identified as an option for treating substance use disorders under Medicaid. The SUPPORT Act directs CMS, within one year of enactment, to provide guidance to states on options regarding federal reimbursement under Medicaid for services and treatment delivered via telehealth, including (1) services addressing the needs of high-risk individuals, (2) education for providers serving drug-impaired beneficiaries through a hub-and-spoke model, (3) services through contracts with managed care entities, (4) services through administrative claiming for disease management activities, (5) services through Delivery System Reform Incentive Payment (DSRIP) programs, and (6) treatment for substance use disorders for Medicaid beneficiaries in school-based health centers.

Separately, the GAO is required to report to Congress not later than one year after enactment on the results of an evaluation of children’s access to services and treatment for substance use disorders under Medicaid, including increasing the number of providers using telehealth in school-based health centers. The evaluation will include an analysis of Medicaid provider reimbursement rates for treating substance use disorders. The GAO will also provide specific recommendations for administrative or legislative action necessary to improve children’s access to care.

The new law directs CMS to report to Congress, no later than one year after enactment, on best practices and potential solutions for reducing barriers to using telehealth to provide substance use disorder treatment and services among pediatric populations under Medicaid.

It also requires the Drug Enforcement Administration (DEA) to promulgate rules for the implementation of special registration for remote providers within one year of enactment.

Disposal of Unused Medication

Safe Disposal Information for Part D Plan Enrollees

Beginning in 2021, Medicare Advantage plans will be required to provide enrollees with information on the safe disposal of prescribed controlled substances including drug takeback programs and in-home disposal options under the in-home risk assessment or through their MTM programs.

Disposal of Unused Patient Medications by Hospice Employees

The SUPPORT Act permits an employee of a qualified hospice program to dispose of a patient’s controlled substances onsite if the disposal occurs after the death of the patient or the controlled substance is expired. In instances where the hospice employee is a physician registered under Section 303(f) of the Controlled Substances Act, he or she may dispose of the patient’s controlled substances if the patient no longer requires the controlled medication because of a change in his or her plan of care.

“Qualified hospice program” is defined as a hospice program that has written policies and procedures for assisting in the disposal of a hospice patient’s controlled substances after their death, and at the time when the controlled substances are first ordered, the hospice program

  • provides a copy of the written policies and procedures to the patient or patient representative and family;
  • discusses the policies and procedures with the patient or representative and the family in a language and manner that they understand to ensure that these parties are educated regarding the safe disposal of controlled substances; and
  • documents in the patient's clinical record that the written policies and procedures were provided and discussed.

At the time following the disposal of the controlled substances, the hospice program

  • documents in the patient's clinical record the type of controlled substance, dosage, route of administration, and quantity so disposed; and
  • documents the time, date, and manner in which the disposal occurred.

The DEA may issue guidance to assist qualified hospice programs in meeting the new requirements.

The new law provides that nothing therein shall be construed to prevent a state or local government from imposing additional controls or restrictions in regulating the disposal of controlled substances in hospice care or hospice programs. It further directs the GAO to study and report back to Congress no later 18 months after enactment on legislative and administrative actions for disposing of controlled substances in a patient’s home.

Disposal Options; Access to Collections and Disposal Sites

The SUPPORT Act directs the Food and Drug Administration to work with manufacturers in establishing safe disposal options for rendering unused drugs non-retrievable and options for dispensing opioids in unit dose packages or packages with a set treatment duration. It also requires the GAO to report to Congress within a year after the date of enactment on the effectiveness of in-home disposal products for controlled substances and packaging technologies including a description of current oversight efforts by the federal government. The US attorney general may make grants to as many as five states to increase the participation of “authorized collectors” of opioids for disposal, including retail pharmacies and hospitals or clinics with onsite pharmacies.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morgan Lewis | Attorney Advertising

Written by:

Morgan Lewis
Contact
more
less

Morgan Lewis on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.